Eirion Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
Eirion General Information
Description
Developer of prescription products intended for aesthetic dermatology. The company's products focus on the treatment of wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying, enabling patients to get rid of problems like lateral canthal lines.
Contact Information
Website
www.eirionthera.comCorporate Office
- 25-K Olympia Avenue
- Suite 200
- Woburn, MA 01801
- United States
Corporate Office
- 25-K Olympia Avenue
- Suite 200
- Woburn, MA 01801
- United States
Eirion Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 3. Early Stage VC (Series A) | 09-Mar-2021 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Spin-Off | 01-Jan-2016 | Completed | Startup |
Eirion Comparisons
Industry
Financing
Details
Eirion Competitors (2)
One of Eirion’s 2 competitors is Amplifica (Drug Discovery), a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amplifica (Drug Discovery) | Venture Capital-Backed | San Diego, CA | ||||
| Kintor | Formerly VC-backed | Suzhou, China |
Eirion Patents
Eirion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026147911-A1 | Topical compositions and regimens | Pending | 30-Dec-2024 | ||
| AU-2024344613-A1 | Topical compositions and uses of pai-1 inhibitors | Pending | 18-Sep-2023 | ||
| EP-4780415-A1 | Topical compositions and uses of pai-1 inhibitors | Pending | 18-Sep-2023 | ||
| WO-2025064449-A1 | Topical compositions and uses of pai-1 inhibitors | Inactive | 18-Sep-2023 | ||
| AU-2020274082-A1 | Delaying peak effect and/or extending duration of response | Active | 14-May-2019 | A61K9/0021 |
Eirion Signals
Eirion Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gore Range Capital | Venture Capital | Minority | ||
| Kinled Holding | Family Office | Minority | ||
| Shanghai Haohai Biological Technology | Corporation | Minority | ||
| Praesideo Management | Hedge Fund | Minority | ||
| Scientific Health Development | Venture Capital | Minority |
Eirion FAQs
-
When was Eirion founded?
Eirion was founded in 2016.
-
Where is Eirion headquartered?
Eirion is headquartered in Woburn, MA.
-
What is the size of Eirion?
Eirion has 10 total employees.
-
What industry is Eirion in?
Eirion’s primary industry is Drug Discovery.
-
Is Eirion a private or public company?
Eirion is a Private company.
-
What is Eirion’s current revenue?
The current revenue for Eirion is .
-
How much funding has Eirion raised over time?
Eirion has raised $43M.
-
Who are Eirion’s investors?
Gore Range Capital, Kinled Holding, Shanghai Haohai Biological Technology, Praesideo Management, and Scientific Health Development are 5 of 7 investors who have invested in Eirion.
-
Who are Eirion’s competitors?
Amplifica (Drug Discovery) and Kintor are competitors of Eirion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process